The American Society of Clinical Oncology (ASCO) issued updated antiemetic guidelines recommending that patients who receive highly emetogenic chemotherapy regimens be offered a 3-drug combination of a neurokinin 1...
The American Society of Clinical Oncology (ASCO) issued updated antiemetic guidelines recommending that patients who receive highly emetogenic chemotherapy regimens be offered a 3-drug combination of a neurokinin 1...
The...